Filing Flows › Companies › Edwards Lifesciences › Timeline
Edwards Lifesciences stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions+23.9% to $102.14
Edwards Lifesciences (EW) stock rose 24% over the last 252 sessions, to $102.14. On the way it reported 4 quarters, its insiders filed 7 open-market trades and 8 Form 144 notices of planned sales, and the company filed 3 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Nov 4, 2026 | Earnings | Earnings: beat the EPS estimate by 8.6% | +4.3% (+2.7% vs SPY) | — | — |
| Aug 31, 2026 | Form 144 | Form 144: Andrew M. Dahl plans to sell $50K | +0.6% (+0.9% vs SPY) | −0.3% (−0.4% vs SPY) | −2.4% (−1.9% vs SPY) |
| Aug 31, 2026 | Insider sale | Dahl Andrew M. sold $50K | +0.6% (+0.9% vs SPY) | −0.3% (−0.4% vs SPY) | −2.4% (−1.9% vs SPY) |
| Aug 28, 2026 | 8-K | Directors and officers: departures, appointments, pay | +0.6% (+0.9% vs SPY) | −0.3% (−0.4% vs SPY) | −2.4% (−1.9% vs SPY) |
| Aug 28, 2026 | Form 144 | Form 144: Annette Bruls plans to sell $238K | +0.3% (+0.5% vs SPY) | −0.2% (−0.4% vs SPY) | −3.5% (−3.0% vs SPY) |
| Aug 28, 2026 | Insider sale | Bruls Annette sold $238K | +0.3% (+0.5% vs SPY) | −0.2% (−0.4% vs SPY) | −3.5% (−3.0% vs SPY) |
| Aug 26, 2026 | Form 144 | Form 144: Daveen Chopra plans to sell $2.9M | −0.1% (−0.1% vs SPY) | −0.1% (+0.4% vs SPY) | −5.8% (−6.2% vs SPY) |
| Aug 26, 2026 | Form 144 | Form 144: Wayne Markowitz plans to sell $113K | −0.1% (−0.1% vs SPY) | −0.1% (+0.4% vs SPY) | −5.8% (−6.2% vs SPY) |
| Aug 26, 2026 | Insider sale | Markowitz Wayne sold $113K | −0.1% (−0.1% vs SPY) | −0.1% (+0.4% vs SPY) | −5.8% (−6.2% vs SPY) |
| Aug 26, 2026 | Insider sale | Chopra Daveen sold $2.9M | −0.1% (−0.1% vs SPY) | −0.1% (+0.4% vs SPY) | −5.8% (−6.2% vs SPY) |
| Aug 11, 2026 | Form 144 | Form 144: Daniel J. Lippis plans to sell $171K | +1.8% (+2.1% vs SPY) | −1.3% (−1.3% vs SPY) | −6.5% (−5.1% vs SPY) |
| Jul 30, 2026 | Form 144 | Form 144: Scott B Ullem plans to sell $4.6M | +1.3% (−0.3% vs SPY) | +3.7% (−1.7% vs SPY) | +4.8% (−0.8% vs SPY) |
| Jul 30, 2026 | Insider sale | Markowitz Wayne sold $13K | +1.3% (−0.3% vs SPY) | +3.7% (−1.7% vs SPY) | +4.8% (−0.8% vs SPY) |
| Jul 28, 2026 | Form 144 | Form 144: Wayne Markowitz plans to sell $819K | +0.8% (+0.5% vs SPY) | +6.7% (+4.3% vs SPY) | +9.0% (+5.4% vs SPY) |
| Jul 28, 2026 | Insider sale | Markowitz Wayne sold $819K | +0.8% (+0.5% vs SPY) | +6.7% (+4.3% vs SPY) | +9.0% (+5.4% vs SPY) |
| Jul 27, 2026 | Form 144 | Form 144: Bernard J Zovighian plans to sell $245K | +0.5% (+0.5% vs SPY) | +4.1% (+3.0% vs SPY) | +9.1% (+5.8% vs SPY) |
| Jul 27, 2026 | Insider sale | Zovighian Bernard J sold $245K | +0.5% (+0.5% vs SPY) | +4.1% (+3.0% vs SPY) | +9.1% (+5.8% vs SPY) |
| Jul 23, 2026 | Earnings | Earnings: beat the EPS estimate by 5.3% | −0.6% (+0.6% vs SPY) | +1.6% (+4.1% vs SPY) | +6.3% (+4.3% vs SPY) |
| May 8, 2026 | 8-K | Directors and officers: departures, appointments, pay | −3.5% (−3.8% vs SPY) | +1.8% (+1.5% vs SPY) | +9.0% (+9.1% vs SPY) |
| May 4, 2026 | 8-K | Directors and officers: departures, appointments, pay | −0.5% (−1.3% vs SPY) | −7.7% (−10.6% vs SPY) | +3.1% (−1.8% vs SPY) |
| Apr 23, 2026 | Earnings | Earnings: beat the EPS estimate by 7.3% | −2.2% (−1.9% vs SPY) | −0.4% (−0.4% vs SPY) | +2.0% (−2.3% vs SPY) |
| Feb 10, 2026 | Earnings | Earnings: missed the EPS estimate by -6.3% | +0.3% (+0.6% vs SPY) | +2.1% (+3.7% vs SPY) | +10.2% (+12.8% vs SPY) |
Insiders’ record here
In the year on the chart, Edwards Lifesciences' insiders reported 0 open-market buys ($0) and 7 sales ($4.4M). Of the 3 old enough to score, 0 were followed by the stock doing what the trade implied over the next 63 sessions (beating SPY after a buy, lagging it after a sale); the median excess return after a buy was — and after a sale +4.4%.
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → Edwards Lifesciences: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.